3T: A Phase II Single Arm Open Label Study of Tucatinib Combined with Trastuzumab and TAS-102 in Molecularly Selected Patients with HER2+ Metastatic Colorectal Cancer
Clinical Trial Grant
Awarded By
Mayo Clinic - Rochester
Start Date
November 20, 2023
End Date
January 30, 2025
Awarded By
Mayo Clinic - Rochester
Start Date
November 20, 2023
End Date
January 30, 2025